Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Hypereosinophilic Syndrome|Systemic Mastocytosis|Chronic Myelomonocytic Leukemia|Dermatofibrosarcoma
Interventions: DRUG: imatinib mesylate
Sponsor: Novartis Pharmaceuticals